Liquorice extract has been used in the treatment of peptic ulcers for centuries without any particular rationale. Its activity is believed to be associated with the glycoside, glycyrrhizinic acid, hydrolysis of which yields glycyrrhetinic acid (1) [3,hydroxy-1 1-oxo-18/8olean-12-en-30-oic acid] . Carbenoxolone sodium (2) is the disodium salt of glycyrrhetinic acid hemisuccinate, and 'Present address: Department of Pharmacology & Therapeutics, University of Dundee, DDI 4HN is marketed as Biogastrone (Berk). It is claimed to be of value in the treatment of gastric ulcer but is of little value in the treatment of duodenal ulcer. Several clinical trials have been reported in recent years on the efficacy of carbenoxolone in gastric ulcer therapy. For instance Doll, Hill, Hutton, and Underwood (1962) , Doll, Hill, and Hutton (1965) (2) (1965) showed that carbenoxolone increased the rate of healing of gastric ulcers. However, Middleton, Cooke, Stephen, and Skyring (1965) did not confirm these results in non-ambulant gastric ulcer patients. Turpie and Thomson (1965) reported a pronounced incidence of troublesome side effects such as oedema, hypertension, and hypokalaemia that seemed to result from the mineralocorticoid activity possessed by carbenoxolone, a factor that limits the dose that can be given (Fletcher, MacKay, and Forbes, 1967) . Doll, Langman, and Shawdon (1968) showed that spironolactone antagonized both the mineralocorticoid side effects of carbenoxolone and its ulcer-healing properties. Doll et al (1962) saw no effect with Biogastrone tablets on duodenal ulcers. Recently, coated capsules of carbenoxolone have been introduced as a suggested treatment for duodenal ulcers (Duogastrone, Berk) .
There is little information in the literature on the pharmacology of carbenoxolone. It is known to possess anti-inflammatory activity (Finney and Somers, 1958) , an action probably related to the release of corticoids from the adrenals (Khan and Sullivan, 1968) . Carbenoxolone uncouples oxidative phosphorylation, being less potent than glycyrrhetinic acid in this respect. Both compounds bind with bovine plasma albumin, carbenoxolone to a greater degree than the parent acid (Whitehouse, Dean, and Halsall, 1967) .
The mode of action of carbenoxolone in helping to heal gastric ulcers is unknown. It has been shown by Parke, Pollock, and Williams (1963) and Iveson, Parke, and Williams (1966) that carbenoxolone is rapidly absorbed into the blood stream from the stomach so that a systemic effect on healing cannot be ruled out. It is excreted in the bile as the glucuronide. Hunt (1965) (Dean, 1968) and it has been suggested that the layer of mucus protects the ulcer from the action of acid and pepsin (Hunt, 1965) .
The experiments described in this paper show that carbenoxolone inactivates pepsin whilst reducing the total acidity of the gastric juice and it is suggested that these effects could contribute to the therapeutic activity of the drug.
As standards for comparisons of the antipeptic activity of carbenoxolone, three preparations were used: (1) glycyrrhetinic acid; (2) Roter (F.A.I.R.), a mixture of bismuth subnitrate, magnesium carbonate, and sodium bicarbonate, claimed to be of value in the treatment of peptic ulceration; and (3) a degraded carregeenan in the form of Ebimar tablets (Evans Medical), previously shown to possess antipeptic activity and to protect experimental animals against peptic ulceration (Levey and Sheinfeld, 1954; Anderson, 1961a and b; Anderson and Harthill, 1967) .
Methods 1 PYLORUS-LIGATED RATS
Female Sprague-Dawley rats (180-220 g) were deprived of food overnight but given free access to 5% dextrose and 0.2 % sodium chloride in distilled water. Solutions were prepared so that 2 ml of solution contained the weight of compound required by 1 kg body weight. Solutions were administered orally in a volume of 2.0 mI/kg. Control animals received only sodium bicarbonate solution at pH 7.0-8.0. The pylorus was ligated while the animals were anaesthetized with 40 mg/kg pentobarbitone sodium given intraperitoneally. Four hours later the rats' stomachs were removed. The contents were centrifuged at 3,000 rpm for 10 minutes and were assessed for volume, total acid concentration, peptic activity, and K+ concentration (see method 2).
A chronic experiment was undertaken to investigate the possibility that the antipeptic activity of carbenoxolone could be cumulative with prolonged dosage, and also the suggested antagonism of carbenoxolone's activity by spironolactone. Three groups of 16 rats each were treated daily with 2 ml/kg of the appropriate solutions. The first group received 10 mg/kg carbenoxolone orally each day, the solution being prepared as described below. A second group received 10 mg/kg carbenoxolone + 2.5 mg/kg spironolactone orally each day, both drugs being dissolved in the same solution. The third control group received a solution of sodium bicarbonate. ThepH of all three solutions was checked and when necessary adjusted to 7.0 with dilute hydrochloric acid. During treatment the weight of food eaten and the volume of water drunk by each cage of rats were recorded for each 24-hour period and expressed as g/100g body weight/day and ml/100 g body weight/day respectively. After 17 days' treatment eight of each of the three groups of rats were subjected to pyloric ligation as described above, and the remaining 24 rats were similarly used after a further six days' treatment. In both cases the final doses of the appropriate solutions were administered before the administration of the anaesthetic and pyloric ligation.
GASTRIC JUICE ANALYSIS METHODS

Pepsin
The method was essentially that of Anson (1938) as modified by Aitken, Spray, and Walters (1954) Pepsin plates Pepsin plates were prepared by the method of Carter and Sykes (1961) . Plates were used in pairs, each pair having 32 cups. Pepsin solution, with or without carbenoxolone, Roter, or Ebimar, was made up in half-strength McIlwaine buffer (pH 3.5) such that the amount of pepsin in the 0.02 ml was either 1 or 10 ,gg. The concentration of the drug was varied, and five or six samples of each concentration were estimated in each assay, the solutions being distributed on the plates in a latin square design. After three hours, when the solutions had been absorbed into the agar, the plates were inverted and incubated at 37°C for 24 hours and then the zones of digestion were measured in two directions at right angles. After averaging the zones produced by each different solution and subtracting the cup diameter, the average zone sizes produced in the presence of the drug were compared with those produced by pepsin alone. The product was crystallized from aqueous methanol and had mp 317-320°C (decomp.). (Finney and Tarnoky (1960) give mp 315-7°C.) (Found: C, 71.6; H, 8.8 . Calc. for C3UH,00,7C 71-6; H, 8.8 %.) It was dissolved in aqueous sodium bicarbonate and the pH was adjusted to 7-0-8-0. One batch of material was used for the acute and in-vitro experiments whilst a second batch of carbenoxolone was employed in the chronic experiment. The glycyrrhetinic acid used was obtained from Fluka A.G. (Switzerland). This did not dissolve completely in bicarbonate and was administered as a suspension in bicarbonate, again adjusted to pH 7.0-8.0. Suspensions of Roter (F.A.I.R.) and Ebimar (Evans Medical) were prepared as described in method 3.
Spironolactone, administered in chronic experiments, was obtained from Aldactone A tablets crushed and dissolved in carbenoxolone volume of gastric juice or in K+ concentration solution.
( Table Ic) . However, a dose-dependent inhibition of peptic activity was observed ( Fig. 1 and 
Pepsin plates
In the pepsin plate experiments, dose-dependent inhibition of peptic digestion similar to that seen in pylorus-ligated rats was observed with carbenoxolone, complete inhibition of 10 gg pepsin being achieved with 250 pgg carbenoxolone (Figure 2 ). The percentage of peptic inhibitioncarbenoxolone concentration curve obtained with 1 ,gg pepsin was parallel to that obtained using 10 ,ug pepsin. Some eight to 10 times more carbenoxolone was required to produce inhibition of 1O,g of pepsin compared with 1 ,ug of peptic.
Both Roter and Ebimar produced inhibition in this experiment, but the concentration of the material required showed that both were considerably less active than carbenoxolone ( Figure  2 ).
Discussion
The results reported here show a hitherto unpublished action of carbenoxolone, namely, its ability to inhibit pepsin both in vivo and in vitro. Carbenoxolone, which is the hemisuccinate of glycyrrhetinic acid, was more potent than glycyrrhetinic acid itself in inhibiting peptic activity and was also more active than both degraded carrageenan and Roter. Of those drugs currently used in the treatment of peptic ulcers, carbenoxolone represents the most potent inhibitor ofpepsin.
Hausmann and Tarnoky (1966, and (1967) , showing that carbenoxolone and glycyrrhetinic acid bind to bovine plasma albumin, support the idea that pepsin could be inactivated by a similar binding mechanism. They found that carbenoxolone bound more readily to bovine plasma albumin than did glycyrrhetinic acid. The effect they reported, however, was small. It is interesting that they found o-[3-0(fl-carboxypropionyl)-18-,-glycyrrhetamido]benzoic acid was slightly more effective than carbenoxolone in its ability to bind with bovine plasma albumin. If proteinbinding capacity is indeed the mechanism by which carbenoxolone inhibits pepsin, one might have expected that this compound would be more effective than carbenoxolone. The differences reported by Whitehouse et al, however, are small and might not be significant in an experiment in vivo.
In these experiments carbenoxolone was a far more potent antipeptic agent than 'Roterized' bismuth (Bateson, 1958; Matts, 1965) or the Ebimar carrageenan substance. The failure to show peptic inhibition with carrageenan may be explained by the hypothesis that carrageenan acts by forming a substrate-inhibitor complex (Anderson and Baillie, 1967.) In the haemoglobin pepsin assay and, to a lesser extent, in the pepsin plate, excess substrate is present. This fact seems relevant when attempting an explanation as to why this compound had only a limited use clinically since stomach contents also contain an excess of substrate whenever food is present.
The mineralocorticoid activity of carbenoxolone has proved to limit the amounts of this drug that can be used clinically, and the limitation of dosage may well explain the variability in results of clinical trials. Doll, Langman, and Shawdon (1968) have shown that the administration of spironolactone in conjunction with carbenoxolone antagonizes both the beneficial effect on peptic ulceration as well as the effects on water retention. These results strengthened the hypothesis that the mineralocorticoid effects of carbenoxolone were essential for activity. Whilst there are some structural similarities between carbenoxolone and spironolactone it is difficult to understand how spironolactone could interfere with the mode of action of carbenoxolone if the latter is acting purely as a pepsin antagonist. To what extent the peptic inhibition contributes to the beneficial clinical results is unknown, but a more potent compound with this action and no mineralocorticoid activity could help to answer this question.
The activity of carbenoxolone in experimental ulceration has been studied in these laboratories using a variety of ulcer models. No significant and consistent effect of carbenoxolone on ulcer formation was found in any of these experimental situations (Ash and Edwards, personal communication). Whilst Dean (1968) did report some protection of Wistar rats against the ulcerogenic effects of the histamine liberator 48/80 by pretreatment with 10 mg/kg/day orally for two weeks, the protective effect he noted was small. Khan and Sullivan (1968) were, however, able to show that carbenoxolone in an oral dose of 25 mg/ kg/day increased the rate of healing of rat gastric ulcers produced by electrocautery. Many workers feel that such studies of ulcer healing are of more value than studies of ulcer prophylaxis.
Whilst mucin stimulation has in the past been group.bmj.com on October 14, 2017 -Published by http://gut.bmj.com/ Downloaded from considered as a possible mode of action of carbenoxolone the results in this paper suggest that peptic inhibition could also be considered. If these are the prinicipal ways by which carbenoxolone helps to increase the rate of healing of gastric ulcers, one begins to understand why it is of value in treating gastric ulcers but of less value in duodenal ulcers. As gastric ulcers coexist with gastric hyposecretion, a given amount of peptic inhibition would be more significant than in duodenal ulcers where the levels of gastric secretion and peptic activity are much higher. Whilst presentation of the drug in capsules which burst in the pylorus could increase its activity in duodenal ulcers, one can speculate that a more potent pepsin antagonist would be far more effective. The recent clinical trial of Duogastrone capsules by Montgomery, Lawrence, Manton, Mendl, and Rowe (1968) would seem to suggest that carbenoxolone preparations are of less value in duodenal ulcer cases.
Molecular models show very clearly that all the functional groups lie along one side of the molecule and it might be suspected that only these groups would be involved in protein binding. The steroid-like backbone of the molecule probably only plays a non-specific role in peptic inhibition as a hydrophobic group. Schlamowitz, Shaw, and Jackson (1968) have shown, using a synthetic dipeptide substrate, that hydrophobicity greatly influences the binding energy of pepsin inhibitors.
If mineralocorticoid and peptic inhibitory effects can be dissociated then it should be possible to design compounds without the limitations of carbenoxolone.
